RaySearch Laboratories AB (publ)
RSLBF is fairly valued
OTC · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$19.81
MARKET PRICE
$19.49
FAIR PRICE
$0.32
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy RSLBF?
No one has priced RSLBF yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when RSLBF's fair price changes
Push notifications when RSLBF's valuation shifts. Available on iOS and Android.
FPI RATING
Strong profitability and low debt levels, but expensive valuation relative to fundamentals.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$15.59
Fair price × 0.80
DISTANCE
21.3%
Price to entry level
At the current price of $19.81, RSLBF trades 21.3% above the conservative entry level of $15.59. This entry level represents a 20% margin of safety below the calculated fair price of $19.49 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate RSLBF's fair price
RaySearch Laboratories AB (publ)'s fair price of $19.49 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $19.81, RSLBF trades 1.6% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting RSLBF's risk profile.
RELATIVE · 30%
Comparing RSLBF's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for RSLBF, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate RSLBF's fair value with your own inputs.
RSLBF DCF Calculator
Pre-filled with RSLBF's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter RSLBF's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of RSLBF's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare RSLBF against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for RSLBF.
Explore on BuliosFAQ
What is the fair price of RSLBF?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for RaySearch Laboratories AB (publ) is $19.49. At the current market price of $19.81, RSLBF trades 1.6% above its calculated fair value.
Is RSLBF overvalued or undervalued?+
RaySearch Laboratories AB (publ) is currently fair based on our valuation model. The stock trades at $19.81, which is 1.6% above the fair price of $19.49. The P/E ratio of 30.1x is a key metric in the valuation.
What is the margin of safety for RSLBF?+
With a 20% margin of safety applied to the fair price of $19.49, the conservative entry level for RSLBF is $15.59. At the current market price of $19.81, the stock trades 21.3% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is RSLBF's fair price updated?+
We update fair price calculations for RSLBF daily after market close. The current fair price of $19.49 incorporates the latest market data and sector multiples.
What factors affect RSLBF's fair price calculation?+
RSLBF's fair price of $19.49 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 30.1x, ROE of 22.8%, and dividend yield of 2.19%.
Is RSLBF a good buy right now?+
At $19.81, RSLBF trades 1.6% above our fair value estimate of $19.49. The stock is currently fair. ROE stands at 22.8% (strong). Fair Price Index provides valuation data — always do your own research before investing.
Does RSLBF pay dividends?+
RSLBF has a dividend yield of 2.19%.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.